Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.

about

Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.

Item

http://www.wikidata.org/entity/Q47568589

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.

@en

Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.

@nl

type

Item

label

Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.

@en

Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.

@nl

prefLabel

Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.

@en

Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.

@nl

P1476

Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.

@en

P2093

Alex F Herrera

http://www.w3.org/2001/XMLSchema#string

Philippe Armand

http://www.w3.org/2001/XMLSchema#string

P2860

Computed Tomography — An Increasing Source of Radiation Exposure

Liquid biopsies: genotyping circulating tumor DNA

Projected cancer risks from computed tomographic scans performed in the United States in 2007

Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment.

Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.

If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma.

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

Cell-free nucleic acids as biomarkers in cancer patients.

Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.

P304

3877-3887

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2017.74.5281

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28933999

http://www.w3.org/2001/XMLSchema#string

P932

5707209

http://www.w3.org/2001/XMLSchema#string